Molecularly targeted therapies that have been developed for a subgroup of non-small cell lung cancer (NSCLC) with endothelial growth factor receptor (EGFR) activating mutations firmly underlined the importance of an improved classification of lung cancer into specific subtypes that qualify for specialized therapeutic strategies. Here, EGFR is linked to lung cancer.